• Gene Edited iPSC
    • CRISPR-Cas9
    • Male or female donors
    Gene Edited iPSC

Genome Edited iPSC Lines

Applied StemCell offers research-ready, isogenic panel of genome edited human iPSCs and their differentiated cells from well-characterized control, parental iPSCs. These gene edited human iPSCs and differentiated neuronal lineage cell lines are ideal for hard-to-model or hard-to-source neurological diseases disease modeling, neurotoxicity screening, and drug discovery and screening studies. 

FAQs
How specific is the GFP reporter driven by the DCXp promoter in the AAVS1-DCXp-GFP knock-in iPSC line?
Is the ASE-9045 APOE-/- iPSC line contain knockout of APOE4 or another isoform?
Products and Services
Application Notes

Disease-specific Knockout iPSC Line: APOE Knockout (ASE-9405)

The ASE-9405 iPSC line is engineered with a bi-allelic (homozygous) knockout for APOE gene (APOE-/-) that has been implicated in Alzheimer’s disease etiology. The parental iPSC is ASE-9109 which is an integration-free, normal karyotype iPSC derived from male, CD34+ cord blood cells. The APOE knockout line can be further differentiated into an isogenic panel of neurons and glia for disease modeling and drug/ toxicity screening applications.

1. Genotyping of APOE-/- bi-allelic KO clone F4: APOE KO

Image 1 - Sequence Alignment between Parental/ Control iPSC Lines

Image 2 - Sequence Alignment between Parental/ Control iPSC Lines

Figure 1. Sequence alignment between parental/ control iPSC line (ASE-9109; male) and APOE-/- clone. The homozygous knockout clone shows a 4 bp deletion in allele 1, a 3 bp deletion in allele 2, and a 4bp insertion in allele 2, as compared to wild type (WT) sequence in parental iPSC line.

2. Expression of Pluripotency Markers

Image 3 - Expression of Pluripotency Markers in iPSC Lines

Figure 2. Expression of pluripotency markers in APOE-/- iPSC line. The homozygous knockout iPSC line, APOE-/-, expresses pluripotency markers OCT4, NANOG, TRA-1-60, and TRA-1-81, indicating pluripotency of the iPSC line after genome editing. Nucleus stained with DAPI (blue).

3. Expression of APOE in neural stem cells differentiated from APOE-/- iPSC-line

Image 4 - Expression of APOE in NSC by qPCR in iPSC Lines

Figure 3. Expression of APOE in neural stem cells (NSC) differentiated from master/ parental iPSC line (ASE-9109) and APOE-/- iPSC line (ASE-9405) was quantified using qPCR. The APOE mRNA was significantly downregulated in the APOE-knockout NSC as compared to expression in the parental/ control iPSC line. 

WT APOE-/- 
1022 -4

Figure 4. APOE Expression in APOE knockout NSCs by microarray. APOE expression in the knockout NSC line was significantly lower than the wild type NSC line.

4. Differentiation of APOE -/- iPSCs into Neurons and GFAP

Image 5 - Differentiation of APOE iPSC Lines into Cortical Neurons and Astrocytes

Figure 5. Differentiation of APOE-/- iPSCs into cortical neurons and astrocytes. The APOE-/- line can be differentiated into cortical neurons (GABA; green) and astrocytes (GFAP; red) to model Alzheimer's disease. Other markers: Neuronal marker (MAP2; red) and nucleus staining (DAPI; blue).


iPSC lines with reporter gene inserted at a safe harbor locus: AAVS1-DCXp-GFP iPSC line (ASE-9502)

ASE-9502 iPSC line is a mono-allelic (heterozygous) knock-in iPSC line engineered with a GFP reporter tag driven by a neuronal-lineage-specific promoter, Doublecortin (DCX) inserted into the AAVS safe harbor locus. The parental iPSC is ASE-9109 which is an integration-free, normal karyotype iPSC derived from male, CD34+ cord blood cells. The AAVS-DCX-GFP Knock-in iPSC line can be further differentiated into an isogenic panel of neurons and glia for disease modeling and drug/ toxicity screening applications.

1. Schematic representation of AAVS-DCXp-GFP reporter construct

Image 1 - Schematic Representation of iPSC lines with Reporter Gene Inserted

Figure 1. Schematic representation of iPSC line with reporter gene inserted in AAVS safe harbor locus, AAVS1-DCXp-GFP (ASE-9502). The reporter gene expression is driven by a neuronal-lineage (neuronal development) specific promoter, Doublecortin (DCXp). The ASE-9502 cell line is derived from master cell line with a ubiquitous promoter expressing a CopGFP reporter gene. After Cre-recombinase mediated cassette exchange (RMCE), a single copy of the DCXp-TagGFP cassette is inserted into the AAVS1 locus.

2. Validation of neuronal-lineage specific reporter cassette knock-in in AAVS1 safe harbor locus

Image 2 - Validation of the DCXp-GFP Reporter Gene Insertion in iPSC Lines

Figure 2. Validation of the DCXp-GFP reporter gene insertion in AAVS1 locus in iPSC line, ASE-9502.  In the AAVS-CAG-GFP master cell line, GFP expression is driven by the ubiquitous promoter, CAG (all cells are stained green for GFP). After RMCE, there is no GFP expression in the iPSCs confirming the absence of a ubiquitous CAG promoter after cassette exchange. When these iPSCs are differentiated into neurons, immunohistochemical characterization showed the co-localization (yellow) of GFP (green) and DCXp-positive neurons (red). The GFP is expressed only in neuronal cells confirming the insertion of the reporter gene in the correct locus. 

Technical Details

Genome engineering in induced pluripotent stem cells (iPSCs) offers the advantage of generating numerous cell line models in an isogenic background along with the parental cell line as an ideal control, where patient-derived primary cells are difficult to obtain. As well, genome editing to introduce and correct mutations in control and disease iPSC lines, is a powerful tool for comparative study of genetic mechanisms involved in cellular/organ development and disease pathology. 

The true potential of the iPSC technology lies in the directed differentiation of iPSCs into a desired cell line lineage, especially into neuronal lineage cells as it provides a more predictive source of central nervous system (CNS) models. These cells are valuable tools for high throughput screening of neurotoxicological and neuroprotective compounds.   

Applications:

We also have disease-specific iPSC lines derived from patients with ALS8, Parkinson’s disease and Diabetes type II patient samples. Please inquire for details on differentiation of these genome-edited cell lines as well as custom differentiation services.

Applied StemCell’s Gene Editing iPSC Lines:

1. Neuronal Disease Specific Isogenic Knockout Lines: 

Isogenic Knock-out Lines

Associated Disease

Description

PARK2 -/-

PD

Biallelic KO

PARK7 -/-

PD

Biallelic KO

PINK1 -/-

PD

Biallelic KO

LRRK2 -/-

PD

Biallelic KO

Park2-/-; Park7-/-

PD

Biallelic KO

Park2-/-; Pink1-/-

PD

Biallelic KO

APOE -/-

Alzheimer's disease

Biallelic KO

SOD1 -/-

ALS

Biallelic KO

DISC1 -/-

Schizophrenia

Biallelic KO

CNTNAP2 -/-

Autism

Biallelic KO

BDNF -/-

CNS

Biallelic KO

2. Lineage-specific Reporter Gene Knock-in Lines:

Knock-in Lineage-specific Reporters

Description

MAP2-Nanoluc-Halotag KI

Neuron reporter

GFAP-Nanoluc-Halotag KI

Astrocyte reporter

MBP-Nanoluc-Halotag KI

Oligodendrocyte reporter

3. Safe Harbor Locus Reporter Gene Knock-in Lines:

Safe-harbor knock-in lines

Description

CAG-GFP, AAVS/Chr19

Ubiquitous reporter

DCXp-GFP

Neuron reporter

 

 

 

Have Questions?

An Applied StemCell technical expert is happy to help, contact us today!

Google